Article - 
Limited access to UNIGEOther version: http://www.intmedpress.com/journals/avt/abstract.cfm?id=1017&pid=88
Highlights
More informations
Scientific Article
unige:7697 
 |
Drug resistance mutations during structured treatment interruptions |
|
| Authors | ||
| Published in | Antiviral Therapy. 2003, vol. 8, no. 5, p. 411-415 | |
| Abstract | BACKGROUND: We assessed whether treatment interruptions induce selection of mutations associated with drug resistance in the Swiss-Spanish Intermittent Treatment Trial (SSITT). Patients had been on HAART without previous failure and had undetectable viraemia for at least 6 months. Their HAART was interrupted for 2 weeks and restarted for 8 weeks. After four of these cycles, treatment was definitively interrupted at week 40. METHODS: Genotypic resistance testing was performed in 87/97 Swiss patients: in those failing treatment before week 40, at the time of first viral rebound > 500 copies/ml off treatment and preceding failure to reach RNA < 50 copies/ml after 8 weeks of re-treatment; for patients without virological failure, on the first sample with HIV-1 RNA > 1000 copies/ml after week 40. RESULTS: Mutations associated with drug resistance were detected in 9/25 (36%) patients with virological failure during the first 40 weeks and in 6/59 (10%) patients after week 40. Overall, drug resistance mutations were detected in 17% of patients, all but two with the 184V/I mutation. Among the 74 patients receiving lamivudine, the M184V/I mutation was detected in 13/74 (17.6%) patients. A wild-type codon at position 184 was detected in previous samples in all but two. The relative risk for virological failure was 2.55-fold higher in patients with the M184V/I mutation than in patients without detectable mutation (P=0.007). CONCLUSIONS: The M184V/I mutation is frequently selected during repeated treatment interruptions. | |
| Keywords | Anti-HIV Agents/ administration & dosage/pharmacology/therapeutic use — Antiretroviral Therapy, Highly Active — Drug Administration Schedule — Drug Resistance, Viral/ genetics — HIV Infections/ drug therapy/virology — HIV Protease/genetics — HIV Reverse Transcriptase/genetics — HIV-1/ drug effects/genetics/physiology — Humans — Lamivudine/administration & dosage/pharmacology/therapeutic use — Microbial Sensitivity Tests — Mutation — RNA, Viral/blood — Reverse Transcriptase Inhibitors/ administration & — Dosage/pharmacology/therapeutic use | |
| Identifiers | PMID: 14640388 | |
| Full text |
Article - Limited access to UNIGE Other version: http://www.intmedpress.com/journals/avt/abstract.cfm?id=1017&pid=88 |
|
| Structures | ||
| Citation (ISO format) | YERLY FERRILLO, Sabine et al. Drug resistance mutations during structured treatment interruptions. In: Antiviral Therapy, 2003, vol. 8, n° 5, p. 411-415. https://archive-ouverte.unige.ch/unige:7697 |
190 hits 
0 download 
Contact an author
Update